The expansion of the partnership between Gilead Sciences, Inc.’s Kite Pharma division and Arcellx, Inc. to include an additional multiple myeloma program as well as lymphomas brings Arcellx additional cash while also providing a potential competitive advantage to the BCMA-directed CAR-T cell therapy program that is the partnership’s focus.
The two companies announced the expanded deal on 15 November, with Kite exercising an option for Arcellx’s ARC-SparX program ACLX-001...